

OFFICIAL  
FAX**EPIGENESIS**  
PHARMACEUTICALS7 Clarke Drive  
Cranbury, New Jersey 08520  
Telephone: (609) 409-6080  
Direct Facsimile: (413) 254-9245  
Main Facsimile: (609) 409-6126**FAX COVER SHEET**

To: Dr. Janet Epps Company: US PTO GAU 1635 Fax No: 703-305-7939

From: Viviana Amzel Date: 11/28/01 Time: \_\_\_\_\_  
Direct Dial: (409) 609-3035 E-Mail: vamzel@epigene.com  
Pages including this: 5 Ref. No.: USSN 09/093,972 (EPI-00672)

**COMMENTS**

Enclosed is the CPA document expressed mailed earlier. Thank you. Viviana

**CONFIDENTIALITY NOTICE**

The information in this fax transmission and the documents accompanying it contain confidential information belonging to the sender which is legally privileged. The information is intended only for the use of the individuals or entities named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this faxed information is strictly prohibited. If you have received this fax in error, please immediately notify us by telephone to arrange for return of the original documents to us.

PTO/SB/29 (10-00)

Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**CONTINUED PROSECUTION APPLICATION (CPA)****REQUEST TRANSMITTAL**Submit an original, and a duplicate for fee processing.  
(Only for Continuation or Divisional applications under 37 CFR 1.53(d))

CHECK BOX, if applicable.

☒ **DUPLICATE**

Address to:

Assistant Commissioner for Patents  
Box CPA  
Washington, DC 20231Attorney Docket No.  
of Prior Application

EPI-00672

First Named Inventor

Jonathan W. Nyre

Examiner Name

Dr. Janet Epps

Group Art Unit

1635

Express Mail Label No.

EL 836 372 650 US

This is a request for a ☒ continuation or ☐ divisional application under 37 CFR 1.53(d),  
(continued prosecution application (CPA)) of prior application number 09/093,972filed on June 9, 1998, entitled Composition, Formulation, Method for Detection & Treatment of Diseases and Conditions Associated with Brain Construction, Alleviation of Pain, etc.**NOTES****FILING QUALIFICATIONS:** The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371. Effective May 29, 2000, a CPA may only be filed in a utility or a plant application if the prior nonprovisional application was filed before May 29, 2000. A CPA may be filed in a design application regardless of the filing date of the prior application. See "Request for Continued Examination Practice changes to and Provisional Application Practice," Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1293 Off. Gaz. Pat. Office (Apr. 11, 2000).**CIP NOT PERMITTED:** A continuation-in-part application cannot be filed as a CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 1.53(b).**EXPRESS ABANDONMENT OF PRIOR APPLICATION:** The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(p) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.**ACCESS TO PRIOR APPLICATION:** The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.**35 U.S.C. 120 STATEMENT:** In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

- ☒ Enter the unentered amendment previously filed on October 26, 2001 under 37 CFR 1.116 in the prior nonprovisional application.
- ☐ A preliminary amendment is enclosed.
- This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4).
  - ☐ **DELETE** the following inventor(s) named in the prior nonprovisional application:  
.....
  - ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto. 11/29/2001 UPN11 TO 000000002 501728 09093972
- ☐ A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.
- Information Disclosure Statement (IDS) is enclosed:
  - ☐ PTO-1449
  - ☐ Copies of IDS Citations

01 FC:231

370.00 CH

(Page 1 of 2)

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box CPA, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
TOTAL CLAIMS (37 CFR 1.16(c) or (d))		-20* =		x \$ _____ =	\$ _____
INDEPENDENT CLAIMS (37 CFR 1.16(b) or (i))		-3** =		x \$ _____ =	\$ _____
MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))				+ \$ _____ =	\$ _____
				BASIC FEE (37 CFR 1.16)	\$ _____
				Total of above Calculations =	\$ _____
				Reduction by 50% for filing by small entity (Note 37 CFR 1.27).	\$ _____
				* Retissue claims in excess of 20 and over original patent. ** Retissue independent claims over original patent.	TOTAL = \$ _____

6. ☒ Small entity status: Applicant claims small entity status. See 37 CFR 1.27.7. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 50 - 1728:a. ☐ Fees required under 37 CFR 1.16.b. ☐ Fees required under 37 CFR 1.17.c. ☐ Fees required under 37 CFR 1.18.8. ☐ A check in the amount of \$ \_\_\_\_\_ is enclosed.9. ☐ Payment by credit card. Form PTO-2038 is attached.10. ☐ Applicant requests suspension of action under 37 CFR 1.103(b) for a period of \_\_\_\_\_ months (not to exceed 3 months) and the fee under 37 CFR 1.17(i) is enclosed.11. ☐ New Attorney Docket Number, if desired \_\_\_\_\_  
(Prior application Attorney Docket Number will carryover to this CPA unless a new Attorney Docket Number has been provided herein.)12. a. ☐ Receipt For Facsimile Transmitted CPA (PTO/SB/29A)b. ☒ Return Receipt Postcard (Should be specifically itemized, See MPEP 503)13. ☐ Other: \_\_\_\_\_**NOTE:** The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below.**14. NEW CORRESPONDENCE ADDRESS**☐ Customer Number or Bar Code Labelor ☒ New correspondence address below

(insert Customer No. or Attach bar code label here)

Name	Viriana Amzel				
Address	EpiGenesis Pharmaceuticals, Inc.				
	9 Clarke Drive				
City	Cranbury	State	NJ	Zip Code	08512
Country	USA	Telephone	609-409-3035	Fax	403-284-9245

**15. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print /Type)

Viriana Amzel, PhD.

Signature

*Viriana Amzel*

Registration No. (Attorney/Agent)

50,930

Date

November 2, 2001